These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29526981)

  • 1. [Dihydropyrimidine dehydrogenase deficiency causes severe adverse effects of capecitabine].
    Inoue H; Sato Y; Shintani S; Tanabe H; Bamba H; Komai Y; Nakamura T; Imai T; Andou A
    Nihon Shokakibyo Gakkai Zasshi; 2018; 115(3):290-298. PubMed ID: 29526981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
    Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
    Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency.
    Bermejo-Pérez MJ; Galeote-Miguel AM; Rodelo-Haad LE; Alés-Díaz I; Durán-Ogalla G; Benavides-Orgaz M
    Chemotherapy; 2014; 60(5-6):353-5. PubMed ID: 26330092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review.
    Hagiwara Y; Yamamoto Y; Inagaki Y; Tomisaki R; Tsuji M; Fukuda S; Fukuda S; Onoda T; Suzuki H; Niisato Y; Tange Y; Ikeda N; Yamada K; Kobayashi M; Akutsu D; Yamada T; Moriwaki T; Narasaka T; Suzuki H; Tsuchiya K
    Intern Med; 2022 Aug; 61(16):2449-2455. PubMed ID: 35110482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
    Kodali S; Bathini V; Rava P; Tipirneni E
    J Gastrointest Cancer; 2017 Mar; 48(1):66-69. PubMed ID: 26744322
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
    Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
    Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection].
    Nagai K; Okuda Y; Ohara Y; Yamamoto M
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):127-9. PubMed ID: 25596695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
    Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
    Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia.
    Sukkarieh HH; AlSagoor T; Alnuhait M; Bustami R; Bryson S; Adem FMK; Abdalla H; Karbani G
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1704. PubMed ID: 36806724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
    Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
    Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
    Tsutsui M; Yamamoto S; Yoshikawa Y; Nakanishi R; Takano K; Osumi K; Akatsu T; Yoneyama K; Nakagawa M; Kanai T
    Int Cancer Conf J; 2018 Oct; 7(4):125-129. PubMed ID: 31149530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants.
    Ishiguro M; Takenaka R; Ogura K; Hiratsuka A; Takeda H; Kawai D; Tsugeno H; Fujiki S; Okada H
    Acta Med Okayama; 2020 Dec; 74(6):557-562. PubMed ID: 33361878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
    Etienne-Grimaldi MC; Pallet N; Boige V; Ciccolini J; Chouchana L; Barin-Le Guellec C; Zaanan A; Narjoz C; Taieb J; Thomas F; Loriot MA;
    Eur J Cancer; 2023 Mar; 181():3-17. PubMed ID: 36621118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.
    Baek JH; Kim JG; Kim SN; Kim DH; Sohn SK; Hong YJ; Lee KB
    Korean J Intern Med; 2006 Mar; 21(1):43-5. PubMed ID: 16646564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus enterocolitis in a patient with dihydropyrimidine dehydrogenase deficiency after capecitabine treatment: A case report.
    Inoue F; Yano T; Nakahara M; Okuda H; Amano H; Yonehara S; Noriyuki T
    Int J Surg Case Rep; 2019; 56():55-58. PubMed ID: 30831507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
    Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
    Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
    Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).
    Casneuf V; Borbath I; Van den Eynde M; Verheezen Y; Demey W; Verstraete AG; Bm Claes K; Haufroid V; Geboes KP
    Acta Clin Belg; 2022 Apr; 77(2):346-352. PubMed ID: 33423619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.